Fuji Pharma Income Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	51,677	46,138	40,889	35,426	33,990
Revenue Growth (YoY)	12.01%	12.84%	15.42%	4.23%	0.58%
Cost of Revenue	30,914	28,294	24,374	20,867	19,239
Gross Profit	20,763	17,844	16,515	14,559	14,751
Selling, General & Admin	10,957	9,231	8,331	7,355	8,340
Research & Development	3,344	3,401	3,184	2,485	2,446
Amortization of Goodwill & Intangibles	90	337	316	283	278
Operating Expenses	15,773	13,963	12,656	10,781	11,402
Operating Income	4,990	3,881	3,859	3,778	3,349
Interest Expense	-330	-196	-121	-77	-53
Interest & Investment Income	-	-	77	43	7
Currency Exchange Gain (Loss)	35	74	127	227	-48
Other Non Operating Income (Expenses)	85	53	212	39	-6
EBT Excluding Unusual Items	4,780	3,812	4,154	4,010	3,249
Gain (Loss) on Sale of Investments	-	3,118	-	-	153
Gain (Loss) on Sale of Assets	-	-	-	-	2
Asset Writedown	-776	572	364	-288	-33
Legal Settlements	-	-	-120	-	-
Other Unusual Items	-4	772	-	-	-1
Pretax Income	4,000	8,274	4,398	3,722	3,370
Income Tax Expense	1,000	2,128	963	1,026	938
Net Income	3,000	6,146	3,435	2,696	2,432
Net Income to Common	3,000	6,146	3,435	2,696	2,432
Net Income Growth	-51.19%	78.92%	27.41%	10.85%	16.64%
Shares Outstanding (Basic)	24	24	24	24	27
Shares Outstanding (Diluted)	24	24	24	24	27
Shares Change (YoY)	0.38%	0.04%	0.03%	-9.58%	-13.77%
EPS (Basic)	122.93	252.81	141.35	110.98	90.52
EPS (Diluted)	122.93	252.81	141.35	110.98	90.52
EPS Growth	-51.37%	78.86%	27.37%	22.60%	35.27%
Free Cash Flow	3,820	1,373	-1,410	-5,755	2,204
Free Cash Flow Per Share	156.54	56.48	-58.02	-236.90	82.03
Dividend Per Share	45.500	42.500	37.000	35.000	29.000
Dividend Growth	7.06%	14.87%	5.71%	20.69%	-
Gross Margin	40.18%	38.67%	40.39%	41.10%	43.40%
Operating Margin	9.66%	8.41%	9.44%	10.66%	9.85%
Profit Margin	5.80%	13.32%	8.40%	7.61%	7.16%
Free Cash Flow Margin	7.39%	2.98%	-3.45%	-16.25%	6.48%
EBITDA	8,955	7,561	6,882	6,523	5,455
EBITDA Margin	17.33%	16.39%	16.83%	18.41%	16.05%
D&A For EBITDA	3,965	3,680	3,023	2,745	2,106
EBIT	4,990	3,881	3,859	3,778	3,349
EBIT Margin	9.66%	8.41%	9.44%	10.66%	9.85%
Effective Tax Rate	25.00%	25.72%	21.90%	27.57%	27.83%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.